An observational study in Esophagogastric Varices and Portal Hypertension, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Shanghai Zhongshan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital — 5 open to participants now, 6 under way, none of them phase 3. Hypertension, Portal · Shanghai Zhongshan Hospital.
Among the 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, and was the 12th registered.
376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.
Browse Hypertension, Portal studies →5 of the 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–80
Shanghai Zhongshan Hospital
Ages 18+
By country, each count listing its studies:
Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 1,384 is above the median of 150 across 135 observational studies indexed under Hypertension, Portal.
Median enrollment 96 across the 5 interventional studies, 1,033 across the 10 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
1 of the studies in Hypertension, Portal by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502729Shanghai Zhongshan HospitalOptimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Hypertension, Portal by Shanghai Zhongshan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a single-center, prospective cohort study based on real-world data. Patients with portal hypertension and esophagogastric varices were enrolled and divided into an endoscopic treatment group and a non-endoscopic treatment group (including patients receiving medical therapy, interventional procedures, or surgical treatment) according to whether they underwent endoscopic intervention. Baseline data, serum metabolites, CT imaging and endoscopic images, liver biopsy pathology, and other multi-omics data were integrated for both groups. Patients were followed up to compare adverse events after variceal treatment, including rebleeding and its causes, hepatic encephalopathy, ascites, subsequent treatments (such as regular endoscopic therapy, NSSB, and TIPS), and survival outcomes. Clinical characteristics of portal hypertension attributed to different etiologies, including hepatitis B, autoimmune liver disease, schistosomiasis, hematological disorders, and chemotherapy-induced liver injury, were compared. The efficacy and safety of endoscopic and interventional treatments for esophagogastric varices were evaluated. Factors influencing rebleeding rates among different treatment groups were analyzed, and reasons for inclusion in different groups were discussed.
Patients admitted with portal hypertension and esophagogastric varices between January 2026 and December 2027 were included. Portal hypertension was defined as elevated portal pressure caused by various etiologies, including chronic viral hepatitis, metabolic-associated fatty liver disease, autoimmune liver disease, chemotherapy-induced liver injury, and hematological disorders. The diagnosis of portal hypertension and esophagogastric varices was confirmed by laboratory tests and imaging studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who receive endoscopic treatment
Patients who received alternative treatments (excluding endoscopic therapy)
Survival
Survival status
Time frame: At 1, 2, 6, and 12 months post-treatment
Adverse events
Post-treatment adverse events included rebleeding (and its causes), hepatic encephalopathy, and ascites
Time frame: At 1, 2, 6, and 12 months post-treatment
Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.
Of 61 non-industry observational studies under Hypertension, Portal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 256. This study's planned 35 months is below that.
Counting every sponsor, half of 65 studies reached it within 42 months; a quarter within 30 and three quarters within 256.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.